Research

The Yale Center for Asthma and Airways Diseases (YCAAD) is a highly regarded academic clinical center recognized for its excellence in education, research, and patient care. The center consists of three programs: the Asthma Program, the Bronchiectasis and Nontuberculous Mycobacteria (NTM) Infections Program, and the Chronic Obstructive Pulmonary Disease (COPD) Program.

Established in 2000, YCAAD provides opportunities for patients with complicated airway diseases to participate in innovative research through industry-sponsored clinical trials and NIH-funded translational research. In addition to advancing cutting-edge research to improve patients’ lives, YCAAD is committed to training the next generation of leaders in the field. The center provides education opportunities for students, residents, fellows, and health care providers around the region on the cutting-edge management of airway diseases.

Publications

2026

Skin Transcriptomics Reveal Shared Molecular Mechanisms for Skin and Lung Involvement in Systemic Sclerosis
Zielonka J, Li N, Liu Y, Yan X, Wang Z, Ramirez M, Figueroa A, Korde A, Yin H, Britto C, Singh I, Sun H, Herzog E, Feghali‐Bostwick C, Hinchcliff M, Ryu C, Gomez J. Skin Transcriptomics Reveal Shared Molecular Mechanisms for Skin and Lung Involvement in Systemic Sclerosis. Arthritis & Rheumatology 2026 PMID: 41930625, DOI: 10.1002/art.70163.
Peer-Reviewed Original Research
Concepts
PrecISE- A Biomarker Stratified Adaptive Trial of 5 Interventions in Severe Asthma: Final Protocol and the Baseline Cohort
Denlinger L, Israel E, Moore W, Georas S, Wright R, Castro M, Peden D, Anstrom K, Bleecker E, Alexander L, Cahill K, Cardet J, Carr T, Cedano J, Chen A, Chupp G, Comhair S, DiMango E, Erzurum S, Fahy J, Fajt M, Gaston B, Jackson D, Jain S, Jarjour N, Kenyon N, Kraft M, Krishnan J, Kumar R, Lugogo N, Martinez F, Marquis M, Pappalardo A, Phipatanakul W, Rank M, Rosenberg S, Salciccioli J, Sanchez M, Smith L, Sumino K, Szefler S, Tang M, Vijayanand P, Wechsler M, Wenzel S, White S, Zeki A, Ivanova A, Bacharier L, Akuthota P, Team N, Bleecker E, Carr T, Moore W, Rank M, Camacho G, Gerald L, Hastie A, Krings J, Martinez F, Merchen J, Meyers D, Nirendran N, Ortega V, Pippins A, Rusk A, Schunk R, Skeps R, Simmons T, Williamson P, Zein J, Israel E, Cardet J, DiMango E, Phipatanakul W, Bailey J, Banzon T, Bartnikas L, Baxi S, Betapudi V, Brick I, Casale T, Cinelli M, Crestani E, Cunningham A, Esty B, Fandozzi ;, Fernandez J, Fitzpatrick E, Flam B, Forth V, Gaffin J, Gentile K, Gueye-Ndiaye S, Haley K, Heromin R, Hauptmann M, Kaage T, Kelly M, Kraemer M, LaBere B, Lai P, Le M, Ledford D, Lee J, Lee J, Lockey R, Macginnitie A, McCarty K, Moss K, Mukharesh L, Pistenmaa A, Pepper A, Pimental M, Queheillalt D, Robinson A, Salciccioli J, Saroya T, Smith C, Trevedi M, Trippa L, Tulchinsky A, Vitiello A, Yee C, Zakar K, White T, Kumar R, Moy J, Rosenberg S, Aalemansour H, Buechler K, Carter T, Fu J, Hixon J, Jackson C, Ji Y, Johnson C, Kalhan R, Kane J, Kaur O, Li G, Lippner E, Makhija M, Maleckar S, Naureckas E, Nyenhuis S, Peters A, Press V, Qureshi M, Ryba D, Sheng J, Smith L, Xu B, Wechsler M, Szefler S, Chupp G, Holguin F, Kraft M, Liu A, Rogers L, Anderson D, Belimezova S, Bitzan J, Bose S, Brock J, Sanchez J, Clark B, Cohn L, Cotarian A, Cruse M, Eisenberg E, Estrom J, Glassmeyer I, Villalobos J, Grant N, Gruberg B, Guntur V, Hay O, Hills A, Hsieh J, Kessler J, Kolakowski C, Miyazawa N, Pak J, Pruitt D, Rhoads S, Sharma S, Stevens A, Tippin B, Valente C, Vicencio A, Wainscoat C, Weber J, Wessels G, White M, Winnica D, Zeitlin P, Denlinger L, Jarjour N, Krishnan J, Agnihotri N, Bach J, Bires N, DeLisa J, Fichtinger P, Floerke H, Fritz B, Grogan J, Guadarrama A, Hasse W, Jackson D, Kaspari R, Kelley R, Klaus D, Lowell P, Larson L, Norwick L, O’Brien M, Palas T, Pappalardo A, Read E, Schraml A, Schiebler M, Sorkness R, Tattersall M, Wollet L, Gaston B, Erzurum S, Teague W, Chmiel J, Ross K, Aronica M, Beck B, Bendy L, Borish L, Chedraoui C, Comhair S, Davis M, Dix A, Fakhry B, Gammell R, Gluvna A, Hamm E, Heskett M, Hu B, Khatri S, Kirwan J, Kloepfer K, Koo M, Labadia M, Marko A, Matheis N, Mey J, Mulya A, Murphy D, Owensby R, Parker L, Pennington E, Roesch E, Sharp J, Smith C, Solanki N, Veri L, Shifflett K, Yang F, Wenzel S, Lugogo N, Bagheri A, Cislo L, Fajt M, Gauthier M, Hadden M, James P, Mohan A, Moore J, Nouraie S, Ramonell R, Romanek R, Sullivan L, Trudeau J, Zhang M, Akuthota P, Jain S, Vijayanand P, Barry J, Beg N, Brickner H, Alexander L, Diaz D, Jafari Y, McKeon N, Fahy J, Kenyon N, Almario M, Charbit A, Cho L, Gale B, Haczku A, Harper R, Houston T, Kain C, Kivler C, Kuhn B, Liu M, McCourt P, Miller J, Nguyen A, Orain X, Peters M, Plough A, Ramirez K, Rossi L, Schivo M, Singapuri M, Teuber S, Tham T, Tompkins D, Vi J, Zeki A, Castro M, Bacharier L, Sumino K, Atha J, Boomer J, Cahill K, Clover A, Dorman V, Hoffman E, Jackson F, Klinck M, Krings J, Madison J, Quigley J, Quinones T, Saxena S, Sharpe M, Troyer J, Yen-Declue H, Zulich A, Ivanova A, Anstrom K, LaVange L, Bagaason S, Britt A, Bryan H, Burbank A, Chen A, Culpepper C, DeMarcus F, Fenu C, Gotman N, Green R, Harrison L, James J, Kosorok J, Kosorok M, Littleton L, Marquis M, O'Neal W, Peden D, Price R, Quibrera P, Ritz C, Sanchez M, Schwartz S, Slye N, Song T, Wilson N, Croxton T, Lu J, Noel P, Bamdad J, Georas S, Wright R. PrecISE- A Biomarker Stratified Adaptive Trial of 5 Interventions in Severe Asthma: Final Protocol and the Baseline Cohort. The Journal Of Allergy And Clinical Immunology 2026 PMID: 41707916, DOI: 10.1016/j.jaci.2026.02.001.
Peer-Reviewed Original Research
Concepts
Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE).
Chupp G, Nagase H, Skowasch D, Devouassoux G, Côté A, Jackson D, Jackson D, Wechsler M, Imber V, McGinniss J, K S, Howarth P, Pavord I. Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE). American Journal Of Respiratory And Critical Care Medicine 2026 PMID: 41738176, DOI: 10.1093/ajrccm/aamag031.
Peer-Reviewed Original Research
This study investigates switching from frequent biologics to twice-yearly depemokimab for severe asthma, showing similar safety and control but slightly higher exacerbation rates.
Full Summary
Aberrant cellular communities underlying disease heterogeneity in chronic obstructive pulmonary disease
Zhang Y, Wei H, Nouws J, Jiang W, Brewster R, Nguyen J, Liang S, Pass S, Wang W, Collin F, Oill A, Kim S, Siller S, Liu J, Zhao A, Hansbro P, Dela Cruz C, Britto C, Gomez J, Cloonan S, Herzog E, Lam T, Banovich N, Raredon M, Zhang X, Mangiola S, Homer R, Kaminski N, McDonough J, Polverino F, Yan X, Sauler M. Aberrant cellular communities underlying disease heterogeneity in chronic obstructive pulmonary disease. Nature Genetics 2026, 58: 376-391. PMID: 41578022, PMCID: PMC12900648, DOI: 10.1038/s41588-025-02480-z.
Peer-Reviewed Original Research
MeSH Keywords and Concepts

2025

2024

See All Publications

Research

Publications

2026

Skin Transcriptomics Reveal Shared Molecular Mechanisms for Skin and Lung Involvement in Systemic Sclerosis

PrecISE- A Biomarker Stratified Adaptive Trial of 5 Interventions in Severe Asthma: Final Protocol and the Baseline Cohort

Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE).

Aberrant cellular communities underlying disease heterogeneity in chronic obstructive pulmonary disease

2025

Sex-biased Gene Expression Underlies Immune Dysfunction in Asthma.

Down Syndrome Alters Type III IFN and Proinflammatory Airway Epithelial Responses to Respiratory Syncytial Virus Infection.

Work Practices and Respirable Crystalline Silica Exposures in Stone Countertop Fabrication Shops

Pediatric Airway Biology and Transcriptomic Assessment of Therapies

Mepolizumab in patients with severe asthma and blood eosinophil counts between 150 and 300 cells per µL: benefits at two years

Impact of Demographics on Mepolizumab Effectiveness in Severe Asthma: One-Year REALITI-A Subanalysis

Military Inhalational Exposures Outside the Theater of Conflict and Chronic Respiratory Symptoms

Cyclic GMP-AMP synthase expression is enhanced in systemic sclerosis-associated interstitial lung disease and stimulates inflammatory myofibroblast activation

Hypersensitivity pneumonitis associated with home mold exposure: A retrospective cohort analysis

Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease

Prospective REALITI-A Study 2-Year Real-World Benefits of Mepolizumab in Severe Asthma

Long-Term Air Pollution Exposure and Severity of Idiopathic Pulmonary Fibrosis: Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry.

Maintenance of an Asthma Intervention Post-Trial: Use of a Patient-Activated Reliever-Triggered Inhaled Corticosteroid (PARTICS) Strategy in Black and Latinx Patients

Silicosis: A Chronic Work-related Lung Disease

Uncovering Transcriptional Endotypes in Pediatric Asthma—A New Lens on Biomarker-Based Clinical Stratification

Absenteeism Among Healthcare Workers: Job Grade and Other Factors That Matter in Sickness Absence

2024

Identification of Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease Subgroups by Machine Learning Implementation in Electronic Health Records.

Sinusitis and rhinitis among US veterans deployed to Southwest Asia and Afghanistan after September 11, 2001

The next frontier Defining and optimizing treatments for patients with type 2 low asthma

Interleukin‐5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils

Does Eosinophil Heterogeneity Translate into Functional Diversity? A Review of the Evolving Paradigm of Eosinophil Heterogeneity in Asthma